The Direct Medical Costs of Diseases Associated with Human Papillomavirus Infection in Manitoba, Canada
| Autor: | Salaheddin M. Mahmud, Gurpreet Pabla, Christiaan H. Righolt |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Economics and Econometrics medicine.medical_specialty Cost estimate Adolescent Total cost Cost-Benefit Analysis Uterine Cervical Neoplasms Drug Costs 03 medical and health sciences Young Adult 0302 clinical medicine medicine Humans 030212 general & internal medicine Medical prescription Child health care economics and organizations Aged Cervical cancer Cervical screening Health economics business.industry Health Policy Public health Papillomavirus Infections HPV infection Manitoba General Medicine Health Care Costs Middle Aged medicine.disease Uterine Cervical Dysplasia Condylomata Acuminata 030220 oncology & carcinogenesis Emergency medicine Female Mouth Neoplasms business |
| Zdroj: | Applied health economics and health policy. 16(2) |
| ISSN: | 1179-1896 |
| Popis: | The total direct cost of screening and treating all human papillomavirus-related diseases (HPV-RD) has not been measured in a single study. Accurate cost estimates are needed to inform decisions on intervention priorities and evaluate the cost-effectiveness of existing programs. We used province-wide clinical, administrative, and accounting databases to measure direct medical costs of HPV infection in Manitoba (Canada). All persons 9 years or older with health insurance coverage in Manitoba between April 2000 and March 2015 were eligible. We identified all persons with an incident HPV-RD and aggregated all medical costs (in 2014 Canadian dollars) related to that condition, including prescription drugs, diagnostic procedures, in-hospital and outpatient treatment, and physician visits. We found that the median cost of treating a case of anogenital warts was $130. An episode of cervical dysplasia had a median cost of $220, compared to $1300 for an episode of cervical carcinoma in situ. The cost of treating HPV-related invasive cancer varied from $15,000 for cervical cancer to $33,000 for oral cavity cancer. Overall, 80% ($145 million) of the total cost was attributable to HPV infection. Cervical screening and follow-up accounted for $96 million (66%) of all costs and this cost component has declined following the introduction of new screening guidelines. Overall, the average direct medical cost of HPV infection was $720 per newborn. The economic burden of HPV remains significant, although changes in cervical screening guidelines, prompted by the introduction of a public HPV vaccine program, appear to have promoted a promising trend towards lower costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink